



# iTOC10

## CONFERENCE

[www.itoc-conference.eu](http://www.itoc-conference.eu)



10<sup>TH</sup> IMMUNOTHERAPY  
OF CANCER CONFERENCE

## THE LEADING INTERNATIONAL CANCER IMMUNOTHERAPY CONFERENCE IN EUROPE

10<sup>th</sup> ImmunoTherapy of Cancer Conference  
March 21 - 23, 2024 • Munich, Germany



CCC MÜNCHEN  
COMPREHENSIVE  
CANCER CENTER



WOLFGANG  
WILMANN'S  
STIFTUNG




DTK Deutsches Konsortium für  
Translationale Krebsforschung



CECOG ACADEMY  
Central European Cooperative Oncology Group

## SCIENTIFIC PROGRAM



# TABLE OF CONTENTS

iTOC10 Committees.....	3
Scientific Programme.....	4 - 8
Poster Presentations.....	9 - 12
Scientific Information.....	13
Satellite Symposium.....	14
Floorplan.....	16
Exhibitors.....	17
General Information.....	18 - 21
Acknowledgements.....	22
Conference Venue.....	23

## WELCOME TO ITOC10!

The 10th ImmunoTherapy of Cancer Conference (ITOC10) to be held from March 21 - 23, 2024 is a European meeting providing a global platform for translational research in the field of immuno-oncology as well as a forum for discussion of early clinical translation and to address its unique challenges.



ITOC10 is organised by the WMA GmbH in scientific cooperation with the ITOC Association, the Tumor Centre in Munich (TzM), the German Cancer Consortium (DKTK), the CECOG Academy, the CAHON, the Wolfgang Wilmanns Stiftung as well as the Comprehensive Cancer Center Munich (CCCM) in Munich. The main goal of the series of ITOC conferences is to provide a unique platform for discussions where all those dedicated to the immunotherapy of cancer can exchange their knowledge and latest findings to advance the oncology drug development and delivery.



# ITOC10 COMMITTEES

## ITOC10 Conference President

- Michael von Bergwelt (LMU, CCC, DKTK, Munich, Germany)

## ITOC10 Chairmen of the Scientific Committee


- Sebastian Kobold (Ludwig-Maximilians-Universität, Munich, Germany)
- Volkmar Nuessler (TZM, Munich, Germany)

## ITOC10 Scientific Committee

- Niroshana Anandasabapathy (Weill Cornell New York, NY, United States)
- Michael Bergmann (Medical University Vienna, Austria)
- Mascha Binder (Universitätsspital Basel, Switzerland)
- Marcus Bosenberg (Yale School of Medicine, New Haven, CT, USA)
- Tanja D. de Gruijl (Cancer Center Amsterdam, The Netherlands)
- Lisa Derosa (Institut de Cancérologie Gustave Roussy, Dep. of Immunotherapy, Villejuif, France)
- Ulrich Jäger (Medical University of Vienna, Austria)
- Sebastian Kobold (Ludwig-Maximilians-Universität, Munich, Germany)
- Volkmar Nuessler (Munich, Germany)
- Johanna Olweus (Institute for Cancer Research, University of Oslo, Norway)
- Chong-Xian Pan (Harvard Medical School, Boston, MA, United States)
- Pedro Romero (Translational Tumor Immunology Group, University of Lausanne, Switzerland)
- Maya Saleh (Department of Life Sciences and Health, University of Bordeaux, France)
- José Saro (CMO LCB-Novimmune, Switzerland)
- Marion Subklewe (Ludwig-Maximilians-Universität, Munich, Germany)
- Eric Tartour (Hôpital Européen Georges-Pompidou, Paris, France)
- Christoph Zielinski (Medical University of Vienna, Austria)

## ITOC Association Board Members

- Sebastian Kobold (Ludwig-Maximilians-Universität, Munich, Germany)
- Volkmar Nuessler (Munich, Germany)
- Michael von Bergwelt (LMU, CCC, DKTK, Munich, Germany)
- Christoph Zielinski (Medical University of Vienna, Austria)





# THURSDAY, MARCH 21, 2024

**08.30**      **Registration Opens**

**09.30 - 09.40**    **Welcome Address:** Michael von Bergwelt, Munich, Germany

**09.40 - 11.10**    **Plenary Session 1: Basic tumor immunology**

Chair: Sebastian Kobold, Munich, Germany & Niroshana Anandasabapathy, New York, NY, USA

09.40 – 10.10    01.01. Tissue resident macrophages and cancer  
Julie Helft, Paris, France

10.10 – 10.40    01.02. Nociception and cancer immunosurveillance  
Sebastien Talbot, Kingston, ON, Canada

10.40 – 11.10    01.03. Understanding T cell metabolism to improve cancer immunotherapy  
Mathias Wenes, Geneva, Switzerland

11.10 – 11.40    Coffee Break

**11.40 - 13.10**    **Plenary Session 2: New targets and new leads**

Chair: Jose Saro, Plan-Les-Ouates, Switzerland & Pedro Romero, Lausanne, Switzerland

11.40 – 12.10    02.01. Type I IFN , DC and anti-tumor immunity  
Stefani Spranger, Boston, MA, USA

12.10 – 12.40    02.02. Immunocytokines  
Dario Neri, Zürich, Switzerland

12.40 – 13.10    02.03. Targeting TBK1 to overcome resistance to immunotherapy  
Russell W. Jenkins, Boston, MA, USA

**13.10 – 13.40**    **Satellite Symposium** - [please see page 14 for details](#)

13.40 – 15.00    Lunch & Poster Viewing

**15.00 – 17.00**    **Plenary Session 3: Exploiting B cells and other cell types**

Chair: Andrea Schmidts, Munich, Germany & Mascha Binder, Basel, Switzerland

15.00 – 15.30    03.01. iPSC-derived strategies for cancer immunotherapy  
Maria Themeli, Amsterdam, The Netherlands

15.30 – 16.00    03.02. Myeloid ontogeny and metabolic rewiring in the tumor microenvironment  
Serena Vegna, Amsterdam, The Netherlands

16.00 – 16.15    03.03. Tertiary lymphoid structures in pancreatic cancer resemble lymphoid follicles in secondary lymphoid organs as sites for initiation and maintenance of anti-tumor T- and B-cell responses  
Kerstin Wennhold, Cologne, Germany

16.15 – 16.30    03.04. Targeted disruption of tumor-borne GDF-15-mediated immunoresistance restores immune checkpoint inhibitor activity in last-line cancer patients  
Christine Schuberth-Wagner, Planegg-Martinsried, Germany



# THURSDAY, MARCH 21, 2024




16.30 – 16.45 03.05. DSP216 blocks HLA-G and CD47 signaling toward immune cells and restores anti-cancer activity  
Lisa Jacob, Groningen, The Netherlands

16.45 – 17.00 03.06. Cancer-specific oral microbiotherapy for cancer immunotherapy  
Chong-xian Pan, Boston, MA, USA

**17.00 – 18.00 Plenary Session 4: ITOC10 Keynote Lecture by Dr. Philip Blom**  
Chair: Christoph Zielinski, Vienna, Austria

04.01. The role of the Homo sapiens in the emergence and the management of the climate crisis

**18.00 – 20.00 Welcome Reception and Poster Viewing** (at the venue)



## 08.15 – 08.30 **Late breaking abstract: Controversies in Immuno-Oncology**

Chair: Michael von Bergwelt, Munich, Germany & Sebastian Kobold, Munich, Germany

08.15 – 08.30 LB 01.01. Targeting IL-2 activated lymphocytes against otherwise incurable multi-drug resistant hematologic malignancies potentially competing with CAR-T cells  
Shimon Slavin, Tel Aviv, Israel

## 08.30 – 09.30 **Plenary Session 5: Microbiome**

Chair: Hendrik Poeck, Regensburg, Germany, Carolina Alves Costa Silva, Villejuif, France

08.30 – 09.00 05.01. Microbiota modulation of cancer immunotherapy  
Carolina Alves Costa Silva, Villejuif, France

09.00 – 09.30 05.02. Impact of microbiome on CAR T cell efficacy  
Christoph Stein-Thöringer, Tübingen, Germany

## 09.30 – 10.30 **Plenary Session 6: Pro & Contra Sessions: adjuvant vs neoadjuvant IO treatment**

Chair: Christoph Zielinski, Vienna, Austria & Lucie Heinzerling, Munich, Germany

09.30 – 10.00 06.01. Pro-Adjuvant  
Alexander Eggermont, Utrecht, The Netherlands

10.00 – 10.30 06.02. Pro-Neoadjuvant  
Christian Blank, Leiden, The Netherlands

10.30 – 11.00 Coffee Break

## 11.00 – 12.30 **Plenary Session 7: Combination therapies**

Chair: Chong-Xia Pan, Boston, MA, USA & Tanja De Gruijl, Amsterdam, The Netherlands

11.00 – 11.30 07.01. Intradermal CpG/tilsotolimod treatment in pT3-4 cNOMO melanoma: efficacy update of the randomized INTRIM trial  
Tanja de Gruijl, Amsterdam, The Netherlands

11.30 – 12.00 07.02. Tuning bispecific antibody application and rationale combinations for optimal therapies  
Marion Subklewe, Munich, Germany

12.00 – 12.30 07.03. The role of TLS in the response to IO agents  
Antoine Italiano, Bordeaux, France

12.30 – 14.30 Lunch & Poster Viewing



## 14.30 – 15.15 **Plenary Session 8: Lifetime Achievement Award**

Chair: Sebastian Kobold, Munich, Germany & Michael von Bergwelt, Munich, Germany

08.01. Deciphering mechanisms of T cell exhaustion

Andrea Schietinger, New York, NY, USA

## 15.15 – 16.30 **Plenary Session 9: Immuno-Monitoring**

Chairs: Michael Bergmann, Vienna, Austria & Eric Tartour, Paris, France

15.15 – 15.45 09.01. Multidimensional dissection of tumor-immune interaction  
Rebekka Schneider-Kramann, Aachen, Germany

15.45 – 16.15 09.02. CODEXing the TME  
Christian Schürch, Tübingen, Germany

16.15 – 16.30 09.03. Characterization of T cell specificity and exercise-induced dynamics of soluble immunological markers before and after high-intensity aerobic exercise (INHALE)  
Katharina Leuchte, Herlev, Denmark

16.30 – 17.00 Coffee Break

## 17.00 – 18.00 **Plenary Session 10: Young Researcher Session (from submitted abstracts)**

Chair: Louisa von Baumgarten, Munich, Germany & Stefan Endres, Munich, Germany

17.00 – 17.15 10.01. Prostanoid-insensitive chimeric antigen receptor modified T cells mediate therapeutic efficacy in solid cancer models  
Janina Dörr, Munich, Germany


17.15 – 17.30 10.02. Combined anti-angiogenic treatment to increase intratumoral persistence of CAR T-cells in lung cancer brain metastases  
Constantin Eberle, Munich, Germany

17.30 – 17.45 10.03. Long lasting alterations of the immunophenotype and cytokine signature of DLBCL survivors results in persisting immune dysfunction  
Giulia Benintende, Erlangen, Germany

17.45 – 18.00 10.04. Spatial transcriptomics identifies metabolic dysregulation as a key driver of T cell exclusion in esophageal adenocarcinoma  
Jasper Sanders, Amsterdam, The Netherlands

18.05 – 19.00 Poster Viewing with Presenters

## 19.30 **iTOC10 Conference Dinner** (access with Ticket only)



**08.00 – 09.00 Plenary Session 11: Reaching new grounds in cellular therapies**

Chair: Michael von Bergwelt, Munich, Germany & Fabian Müller, Erlangen, Germany

08.00 – 08.30 11.01. CD19 CAR T in SLE  
Fabian Müller, Erlangen, Germany

08.30 – 09.00 11.02. TIL have come back of age in Melanoma  
Troels Holz Borch, Herlev, Denmark

**09.00 – 10.30 Plenary Session 12: Cell therapies in hematologic oncology**

Chair: Marion Subklewe, Munich, Germany & Ulrich Jäger, Vienna, Austria

09.00 – 09.30 12.01. Leveraging metabolites to boost CAR T cell activity in hematology  
Hendrick Poeck, Regensburg, Germany

09.30 – 10.00 12.02. Cellular immunotherapy beyond CAR T cells in hematology  
Jianzhu Chen, Cambridge, MA, USA

10.00 – 10.30 12.03. New approaches for cellular therapies in AML  
Saar Gill, Philadelphia, PA, USA

10.30 – 11.00 Coffee Break

**11.00 – 12.30 Plenary Session 13: Cell therapies in solid oncology**

Chair: Maik Luu, Würzburg, Germany & Johanna Olweus, Oslo, Norway

11.00 – 11.30 13.01. CAR-T in prostate cancer  
Vivek Narayan, Philadelphia, PA, USA

11.30 – 12.00 13.02. Engineering cytokine functionalities in CAR T cells  
Saul Priceman, Duarte, CA, USA

12.00 – 12.15 13.03. Empowering TCR-T cells for adoptive therapy for solid tumor through engineering with PD-1-based chimeric costimulatory switch proteins  
Elfriede Noessner, Munich, Germany

12.15 – 12.30 13.04. Improving the efficacy of TCRtg T cell therapy for solid tumors with mRNA-based vaccination  
Janna Krueger, Tübingen, Germany

12.30 – 12.45 13.05. A Novel Approach for Neoantigen Discovery from Splicing Factor Mutated Cancers  
Teryn Mitchell, New York, NY, USA

**12.45 – 13.15 Plenary Session 13: Best Poster Awards & Closing Remarks**

Chair: Tanja De Gruijl, Amsterdam, The Netherlands

**13.15 – 14.00 Farewell & Lunch**





# POSTER PRESENTATIONS



## 01. Emerging concepts / New Agents

P01.01. | Isoliquiritigenin attenuated metastatic development of pancreatic cancer by regulation of the tumor microenvironment and reactivation from chemoresistance

Joshua Ko, Kowloon Tong, Hong Kong

P01.02. | BIUX2X2

Shan Han, Heidelberg, Germany

P01.03. | Enhancing NK cell cytotoxicity against tumor cells with a novel self-delivering RNAi compound targeting Cbl-b

Melissa Maxwell, Marlborough, United States

P01.04. | Withdrawn

P01.05. | Withdrawn

P01.06. | Overcoming resistance to ICI therapy by downregulating the expression of Neuropilin-1 with antisense oligonucleotides

Richard Klar, Planegg, Germany

P01.07. | Intracellular and extracellular biochemical activities of V-domain Ig-containing suppressor of T cell activation or VISTA

Vadim Sumbayev, Chatham Maritime, United Kingdom

P01.08. | Discovery of CRD1601, a potent and selective HPK1 inhibitor with robust in vivo anti-cancer activity

Ritesh Shrivastava, Noida, India

P01.09. | CRD3874-SI: a novel allosteric STING agonist with high systemic tolerability

Sandip Middya, Noida, Indonesia

P01.10. | Real-time interaction cytometry reveals different binding kinetics of antibodies targeting membrane proteins on fixed versus living cells

Vivien Hafner, München, Germany

## 02. Tumor microenvironment and microbiome in Immunotherapy

P02.01. | Herpesvirus entry mediator - a two-way switch for immunity

Jiixin Xia, Changsha City, Hunan Province, China

P02.02. | Spectral flow cytometry reveals immune regulation of detailed lymphocyte and myeloid populations in neuroblastoma

Anne Borst, Utrecht, Netherlands

P02.03. | Ready-to-use multiplex immunofluorescence assay panels provide reliable deep spatial phenotyping for immuno-oncology applications.

Arne Christians, Hannover, Germany

P02.04. | Withdrawn

P02.05. | AATF(Che-1) RNA polymerase II binding protein overexpression in BCP-ALL cells controls NK-cell proliferation through IL15 expression


Matteo Caforio, Roma, Italy

P02.06. | Integrated multi-omics unraveled a basal cell-dependent signature predictor of outcome and immunotherapy response in LUSC

Jianlong Jia, München, Germany

P02.07. | Trial in progress: Anti-PD1, Capecitabine, and Oxaliplatin for the first-line treatment of dMMR esophagogastric cancer (AuspiciOus-dMMR): a proof-of-principle study (AuspiciOus)

Joris Bos, Amsterdam, Netherlands





# POSTER PRESENTATIONS

P02.08. | Immune-related protein changes due to standard of care therapy in recurrent ovarian cancer patients  
Julie Kempeneers, Leuven, Belgium

P02.09. | Correlation of NK cell activity depending on TNF receptor expression on stem cells  
Vladimir Jurisic, Kragujevac, Serbia

P02.10. | Simplifying High-Parameter Phenotypic and Functional Characterization of Cancer Immune Cells  
Anne-Sophie Thomas-Claudepierre, Paris, France

P02.11. | 50-Parameter Flow Cytometry by CyTOF Empowers Comprehensive Single-Cell Immune Profiling of Pulmonary Immunosenescence in Aged Mice  
Anne-Sophie Thomas-Claudepierre, Paris, France

P02.12. | Immuno-Oncology Imaging Mass Cytometry Study of the Structural and Cellular Composition of the Tumor Microenvironment in Human Cancers  
Anne-Sophie Thomas-Claudepierre, Paris, France

P02.13. | Identifying Pathophysiological Features of Mouse Tumors Using Imaging Mass Cytometry  
Anne-Sophie Thomas-Claudepierre, Paris, France

P02.14. | High-Plex Co-Detection of RNA and Protein to Explore Tumor-Immune Interactions Utilizing RNAscope With Imaging Mass Cytometry  
Anne-Sophie Thomas-Claudepierre, Paris, France

## 03. Vaccine Therapy

P03.01. | Efficacy and toxicity of BCG therapy in bladder cancer  
Suryakanta Acharya, Lakhimpur, India

P03.02. | Development of an antitumor vaccine approach based on the delivery of messenger RNA using a cell penetrating peptide  
Mohammed Sebane, Strasbourg, France

P03.03. | Withdrawn

## 04. Precision Medicine Meets Immunotherapy (Immuno-Monitoring)

P04.01. | Early recovery of radiation induced lymphopenia in NSCLC stage III lung cancer: correlation with prognosis in a prospective study  
Thomas Philipp Hofer, Munich, Germany

P04.02. | Imaging mass cytometry reveals the spatial network of immune cells in neuroblastoma  
Francisca Bergsma, Utrecht, Netherlands

P04.03. | Immuno-Analytics of Patients with Gastric Cancer: Impact of Systemic Polychemotherapy on Peripheral T-Cell Fitness and Immunologic Features of Gastric Cancer Tissue  
Anna Reischer, Munich, Germany

P04.04. | Single cell transcriptomics reveals cancer associated fibroblasts enable modeling of tumor associated macrophage like phenotypes and treatment responses in primary colorectal cancer organoid cultures  
Julijan Kabiljo, Wien, Austria

P04.05. | New non-invasive, label-free monitoring approach for 2D and 3D cell culture  
Anna Jötten, Munich, Germany

## 05. Immunometabolism

P05.01. | Sensitizing immunotherapy refractory prostate cancer with optimized ketogenic diet regimen and epigenetic reprogramming  
Xin Lu, Notre Dame, United States

P05.02. | Investigating the kinetics of CD3 binding and trafficking in real-time  
Paolo Zucchetti, Uppsala, Sweden



# POSTER PRESENTATIONS

## 06. B cells in IO

P06.01. | Gain-of-function CARD11 signalling in B cells causes pathological lymphoproliferative disease in mice which is strictly dependent on MALT1 activity  
Andreas Kratzert, Munich, Germany

P06.02. | Spatio-functional Characterization of Tumor-infiltrating B cells in the Tumor Microenvironment of Cutaneous T cell Lymphoma  
Sabine Oganesian, Munich, Germany

P06.03. | Withdrawn

## 08. Local IO

P08.01. | Novel approaches for investigating LAG3 mechanisms of action  
Sara Bodbin, Uppsala, Sweden

## 09. Cell Therapy in Solid Tumors

P09.01. | Adapting immune cells to the hypoglycemic tumor microenvironment by solute carrier 2a1 (Slc2a1/GLUT1) overexpression  
Martin Kirmaier, Munich, Germany

P09.02. | Loading of CAR-T cells with superparamagnetic iron oxide nanoparticles allows their magnetic targeting for local induction of antigen-specific anti-tumor responses  
Felix Pfister, Erlangen, Germany

P09.03. | Loading of T cells with superparamagnetic iron oxide nanoparticles gives them magnetic controllability while retaining antigen-specific effector functions  
Lucas Carnell, Erlangen, Germany

P09.04. | Isolation of a high avidity TCR targeting a newly identified epitope of a common cancer testis antigen expressed by solid tumors  
Emina Sivo, Berlin, Germany

P09.05. | Novel A20 based therapeutic strategies to fight lung cancer  
Monika Homolya, Vienna, Austria

P09.06. | Establishing a mouse model to visualize limitations of CAR-T cells activity in solid tumors  
Baptiste Arnaud, Paris, France

P09.07. | Determining potency, activation and expansion of antigen specific T cells  
B. Hansen, Virum, Denmark


## 10. Cell Therapy in Haematologic Diseases


P10.01. | Nutritional and immunometabolic measures for risk assessment in allogeneic hematopoietic stem cell transplantation  
Hannah Thurisch, Munich, Germany

## 11. Combination Therapy

P11.01. | Oncological outcomes of laparoscopic versus open radical total gastrectomy for upper-middle gastric cancer after neoadjuvant chemotherapy  
Shen Li-Li, Fuzhou, China

P11.02. | A complex human tumor organoid model consisting of malignant cells, fibroblasts and immune cells enlightens the effect of chemotherapy-induced senescent tumor cells on NK-cell anti-tumor responses  
Daphni Ammon, Vienna, Austria





# POSTER PRESENTATIONS

## 12.Young Researchers Session

P12.01. | Utilizing radiation to improve adoptive cell therapy with tumor infiltrating lymphocytes  
Nina Obertopp, Tampa, United States

P12.02. | Adaptor P329G-directed CAR T cells for modular targeting of AML  
Sophia Stock, Munich, Germany

P12.03. | Heterotypic CD8 T cell clusters isolated from clinical samples are distinct and enriched for antitumor activity  
Sofía Ibáñez Molero, Amsterdam, Netherlands

P12.04. | Adherence to clinical guidelines for managing febrile neutropenia inpatients undergoing hematopoietic stem cell transplantation: Are we inclined to follow the recommendations of IDSA and NCCN in LMIC?  
Kashif Ali, Karachi, Pakistan

P12.05. | Cellular biosensors to study protein interactions relevant to immunotherapy  
Maximilian Funk, Munich, Germany

P12.06. | GLP-compliant validation of a FluoroSpot assay to monitor tumor neoantigen vaccinations in preclinical mouse models  
Alexandra Mauthe, Straßberg, Germany

P12.07. | AI-enhanced quantitative assessment of T cell cytotoxicity using label-free live-cell imaging on micro-pattern for high-throughput investigation of T cell quality and moderation by tumor microenvironment  
Jincheng Cao, Munich, Germany

P12.08. | Targeting tumor-reduced drug accessibility to counteract organ-specific resistance to anti-CD22 immunotoxins  
Franziska Gsottberger, Erlangen, Germany

P12.09. | Expanded T cell clones in neuroblastoma persist throughout chemotherapy and display a druggable dysfunctional profile  
Elisa Zappa, Utrecht, Netherlands

P12.10. | In vivo dynamics and anti-tumor effects of B7-H3-directed CAR T-cells in an orthotopic medulloblastoma mouse model  
Julika Herold, Munich, Germany

P12.11. | RECQL4 promotes immune evasion and limits response to anti-PD-1 therapy and survival in melanoma patients  
Sara Egea-Rodriguez, Munich, Germany

P12.12. | The tumor microenvironment of epithelial ovarian cancer: exhausted and immunosuppressive  
Alexandra Leutbecher, Munich, Germany



# SCIENTIFIC INFORMATION

## Projection and Technical Setting

PowerPoint is the only communication tool available in the session hall. Overhead projection, slide projection or flipcharts are not available.


- Speakers are kindly asked to observe that only the computer provided by the venue may be used for showing your presentations. PowerPoint presentations can be checked and handed in at the speakers' preview desk or uploaded via USB Stick in the lecture room directly.
- All PowerPoint presentations should be checked/handed in at least 2 hours before the session starts.
- If you are doing more than one speech during the congress, you may upload all your presentations at the same time and they will be sent to the session hall at the time of your session.
- The PowerPoint handling and distribution system is optimized for MS PowerPoint 2007 (Office 2007) and "\*.pdf" (Adobe Acrobat)-files. The uploading of "DVD-Movies" is not supported.
- The supported data media is USB-Memory Key. You may want to carry a second key/CD as a back-up in case there is any insoluble technical problem. All needed files (including the movie files!) - have to be saved on the data media. Presentations can also be taken off speakers notebooks at the Preview centre.
- The fonts that are used in the presentations should be "Latin-based fonts". If the speaker needs special fonts, they should be stored as "embedded fonts" with the presentation (File -> save as "name of presentation" and under "tools" -> save options mark the checkbox "embed True type fonts" and select "embed all characters").
- When using mathematical symbols please use these which are available under Latin fonts (unicode or DOS: Western Europe). These can be shown without any problems in Office 2007.
- As format for embedded movies "MPEG2 - movies" are preferred (but can also be \*.avi, \*.wmv ). If Codecs are used, the Code package DIVx in the current version, which can be found under [www.divx.com](http://www.divx.com), should be chosen.
- Presentations should be saved as "\*.ppt", "\*.pptx" (= PowerPoint) or "\*.pps", "\*.ppsx" (=PowerPoint Slideshow) - file and movies as separate files on the data media.
- The computers and projectors will be set up and optimised for resolution ratio 16:9.
- These guidelines should be seen as a matter of improving the effectiveness of the preview system and in consequence also the speakers comfort.


### Speaking Time

The chairpersons will be strict in allowing no more than the time allotted to presentations and discussions following the presentations. Remember to allow some time for the changeover of speakers and chairperson's introduction, and for questions and discussion.

### Commercial Disclosure information

Authors are requested to disclose possible conflicts of interest on the first slide. A conflict of interest is any situation in which a speaker or immediate family members have interests, and those may cause a conflict with the current presentation. Conflicts of interest do not preclude the delivery of the talk, but should be explicitly declared. These may include financial interests (e.g. owning stocks of a related company, having received honoraria, consultancy fees), research interests (research support by grants or otherwise), organisational interests and gifts.





# SATELLITE SYMPOSIUM

Thursday, March 21, 2024

13.10 - 13.40 hrs

Lecture Room 3

## Quantitative Spatial Multiplexing with CellScape Enables Immunophenotyping in Oncology

- Oliver Braubach PhD  
Canopy Biosciences
- Veronika Braubach  
Technical University of Munich



# Spatial Biology Without Limits



Find the most versatile solutions to empower your spatial biology and single-cell omics research:

- CellScape™ Precise Spatial Multiplexing, highly multiplexed, high-resolution imaging for quantitative spatial phenotyping
- Canopy Spatial Services, your partner for accelerating discovery and translational research



Visit us at iTOC Booth 12 and Poster P02.03


Save a seat at our Satellite Symposium:


## Quantitative Spatial Multiplexing with CellScape Enables Immunophenotyping in Oncology

Oliver Braubach, PhD, Canopy Biosciences

Veronika Engelsberger, Technical University of Munich

Thursday, 21 March | 13.10 - 13.40 | Lecture Room 3









# EXHIBITORS



EXHIBITOR	STAND #
ariadne.ai	2
Novogene	4
STEMCELL Technologies	6
Standard BioTools	8
OMNI Life Sciences	10
Canopy Biosciences	12
Agilent Technologies	14
Lunaphore Technologies	16
LGC Standards	18
Promega	20
Immudex	22
New England Biolabs	26





# GENERAL INFORMATION

## ORGANIZER

### WMA GmbH

#### Conference & Society Management

- Contact: Catherine Tomek
- E-mail: itoc@wma.co.at
- Tel.: +43 1 405 13 83 18
- Website: www.wma.co.at



## SPONSORSHIP AND EXHIBITION MATTERS

Rose International

Exhibition Management & Congress Consultancy bv

- Contact: Flora van Laer
- E-mail: fvanlaer@rose-international.com
- Tel.: +31 70 383 8901



## CONFERENCE VENUE


Klinikum der Universität München

Campus Großhadern

Lecture Room 3

Marchioninistrasse 15

80336 Munich, Germany



## HOW TO REACH THE VENUE

Subway:

Metro Line U6 from Marienplatz to the final stop at the Klinikum Großhadern

Bus: Main Bus Line Nr. 56

Regional Buses 266 and 269

See also <https://efa.mvv-muenchen.de>

## Cancellations and Refunds

Registration fees may be refunded if written cancellation has been received as follows:

until December 12, 2023: 50% refund

after December 12, 2023: no refund

The cancellation will not be effective until a written acknowledgement from the Congress Office is received. In the case of over-payment or double payment, refund requests must be made in writing and sent to the Congress Office by e-mail. No refunds will be granted for unattended events or early termination of attendance, in case of cancellation of speakers or any other incidents during the conference, which are beyond the control of the conference organisers.

No exceptions to the refund policy can be made, including health or family issues. By registering for ITOC10, participants agree that neither the organising committee nor the Congress Office assume any liability whatsoever.

## Certificate of Attendance

Confirmations of attendance will be issued electronically after the conference to all registered participants after completion of an online survey.

## Accreditation

The 10th ImmunoTherapy of Cancer Conference, Munich, Germany (March 21 - 23, 2024) has been granted a total of 23 continuing medical education credit points by the Bavarian State Chamber of Physicians | Bayerische Landesärztekammer (BLAEK). The number of credits stated applies for a full participation in the conference..



# GENERAL INFORMATION

## Badges

For security reasons, badges will be checked upon access of the conference areas. Delegates are therefore requested to wear their badge at all times during the conference.

## Catering

- Coffee breaks and the welcome reception have been scheduled in the exhibition area. Exact times are listed in the programme overview.
- Lunch tickets had to be pre-ordered and cannot be purchased onsite.

## Currency

The official currency of Germany is the Euro (EUR).

1 EUR = 1,08 USD = 0,85 GBP = 162 JPY = 0,95 CHF = 11,20 SEK = 7,45 DKK = 1,66 AUD = 1,46 CAD | *as per date of printing*

## Exhibition

The exhibition is held on level 2 next to the main lecture room hall 3. Entrance is free for registered delegates but limited to healthcare professionals, press and exhibitors.

## Insurance

By registering to the ITOC10, participants agree that neither the organising committee nor the congress office assume any liability whatsoever. Participants are requested to make their own arrangements for health and travel insurance. The conference fee does not include insurance.

## Language & Translation

The official language of the conference is English. No simultaneous translation is provided.

## Liability

In registering for ITOC10 participants agree that neither the organising committee nor the congress office assume any liability whatsoever. Participants are requested to make their own arrangements in respect of health and travel. Furthermore, the organisers cannot assume any liability for changes in the programme due to external or unforeseen circumstances and force majeure.

## Opening hours of the registration desk

March 21, 2024: 08.30 - 18.00 hrs CET

March 22, 2024: 07.45 - 18.00 hrs CET

March 23, 2024: 07.30 - 13.15 hrs CET

## Registration Details

Registration Fees in EUR (all fees include 19% German VAT)


	Early Bird until October 30, 2023	From October 31, 2023 to January 25, 2024	From January 26, 2024 and On-Site
Academia	EUR 465,-	EUR 565,-	EUR 665,-
Junior Participant <sup>(1)</sup>	EUR 115,-	EUR 145,-	EUR 190,-
Industry	EUR 765,-	EUR 865,-	EUR 965,-
Foundations & Charities	EUR 240,-	EUR 290,-	EUR 340,-
Press / Media	no fee	no fee	no fee

<sup>(1)</sup>The "Junior Participant" registration is available for Students under 30 years of age. Please provide a copy of a student ID at the moment of your registration.

Payments were to be made without charges to the beneficiary.

Any bank charges will be claimed.

Please be informed that onsite payment by creditcard is preferred.





# GENERAL INFORMATION

## What is covered by the registration fee?

- Admission to all scientific sessions
- Admission to all poster sessions
- Admission to the exhibition
- Abstract book and programme
- Coffee Breaks
- Welcome Reception

## Twitter

The 10th Immunotherapy of Cancer Conference is present on Twitter @ITOCconference. We invite you to follow us on Twitter and to engage and discuss with your colleagues.

## Photographs, Video-Streaming, etc.

The Organiser may without the further consent of the participants use and release pictures and videos taken during the Conference for reports of the Conference and/or in future marketing materials. By registering to this conference attendees agree that photographs or sound or video recordings taken during the conference that could include recognizable images or voices of those in attendance may be posted on the conference website. All recordings are treated sensitively and discreetly. Names will not be published. The Conference is held in a public space, therefore we do not prohibit participants, exhibitors, sponsors, or news organisations from photographing, video or audio-taping some Conference activities. The organiser reserves the right to use images taken at the Conference with your photograph and/or likeness on social media and/or in future marketing materials. The organiser is NOT responsible for individual attendee's use of your image or likeness.

## Policies

ITOC10 is accessible to all registered delegates. Children and members of the public are not permitted in the exhibition area or any room hosting an industry activity. In addition, the ITOC10 conference asks delegates and faculty to refrain from taking children and accompanying adults to any sessions or practical demonstrations. In the event that children are required to enter the conference centre, they should be supervised by an adult at all times and observe the restrictions that apply to limited access areas. In the event that a member of public is invited to participate in the ITOC10 conference scientific programme, they should be accompanied by a qualified healthcare professional or ITOC10 representative observing the ITOC10 restrictions where appropriate.

## Poster Removal

The organisers cannot assume any liability for loss or damage of posters displayed in the poster area. **Posters that were not removed after the last coffee break on Saturday, March 23, 2024, will be discarded and will neither be kept nor mailed to the author after the meeting.**

## Safety - Crime

Visitor safety is generally adequate, like in any other major European city. You can walk everywhere using common sense. Pick pocketing in heavily visited tourist zones or in public transport lines might be a concern. Unfortunately experience has shown that some basic precautionary measures should always be kept in mind in any city:

- Do not carry important items like flight tickets, passports etc. with you when visiting the conference or strolling through the city, leave them in the hotel safe during your stay. Rather carry a Xerox copy of your passport or an identity card with you.
- Try not to carry all documents, money, credit cards and other essential items and valuables in one bag. If it is lost or stolen, everything will be gone and might be difficult to replace on short notice, especially passports and visa to return to your country of residence.
- Take off your name badge when leaving the conference venue, it will make you easily identifiable as a tourist.

## Smoking Policy

ITOC10 is a "No-smoking-Conference".



# GENERAL INFORMATION

## Social Media Policy

ITOC10 supports the use of social media around its conferences and events in order to network with colleagues and friends attending the meeting. Please do however respect the ITOC10 social media guidelines, including the following:

DOs:

- Follow ITOC10 on Twitter (@ITOCconference) and use the meeting hashtag to follow the latest updates and join in the conversation about the conference.
- You may tweet about content of the talks, unless the speaker explicitly asks you not to share either the entire talk or specific details or slides.
- Communicate in a respectful and considerate way, and show your criticism in a fair, constructive and professional manner.
- Do remember that people who will read your postings or tweets are not necessarily professionals, but also patients, policymakers, members of the media, and the general public.

DON'Ts:

- The use of photography in oral and poster sessions at the ITOC10 conferences is allowed, unless indicated differently by the author on one or all of their slides or their poster. Hence posting pictures or videos of presentations (in parts or as a whole) carrying a "no picture" symbol on any social media platform, blogs, or websites, etc., is strictly prohibited.
- Do not capture or redistribute data presented at conferences as this may jeopardise the subsequent publication of the data in a scientific journal. Powerpoint presentations marked with a "no picture" symbol must not be photographed under any circumstances.

Do respect journal embargo policies and the work of your colleagues!

- Refrain from engaging in personal attacks or showing rude behaviour.
- Offensive and disrespectful behaviour, sales-oriented, self-promoting, or otherwise inappropriate comments will not be tolerated.
- Participants should not post copyrighted or trademarked material or material protected by other intellectual property rights.

The views and opinions posted on ITOC10's social media do not necessarily reflect the views, opinions, or policies of the ITOC association, its Board or membership. The ITOC reserves the right to remove comments it deems to be inappropriate.

## Staff

If you should have any questions, the congress staff will be pleased to help you.

## Networking Events

### Welcome Reception

Day: Thursday, March 21, 2024

Time: 18.00 hrs

Location: exhibition & poster area of the conference venue

*No fee for registered participants, but registration is mandatory!*

### Conference Dinner

Day: Friday, March 22, 2024

Time: 20.00 hrs

Location: Restaurant "Haderner Augustiner"


Contribution towards expenses EUR 70,-


Event for registered participants ONLY!

*Tickets had to be pre-ordered - only a limited amount of tickets is available onsite and will be sold on a first-come-first-served basis.*

## WiFi

Free WiFi (Bayern WLAN) is available for participants throughout the conference venue





# ACKNOWLEDGEMENTS

The organisers gratefully acknowledge the support of the following institutions and companies:



## Grants

This activity is supported by a grant from **Pfizer Inc.**

USD 5.000,-

This activity is supported by an educational grant from **Genmab US, Inc.**, who has had no influence on, control of, nor input into the development or performance of the 10th ImmunoTherapy of Cancer Conference.



USD 10.000,-

We herewith confirm that all sponsorship income is free of any attempt to influence the programme, individual sessions, subjects for discussions, content or choice of faculty members



## KLINIKUM DER UNIVERSITÄT MÜNCHEN - CAMPUS GROSSHADERN

LECTURE ROOM 3, HÖRSALTRAKT



# SAVE THE DATES!

Mark your calendars and save the dates for the

## 11<sup>th</sup> ImmunoTherapy of Cancer Conference in 2025!

Join us as we convene once again to advance research, foster collaboration, and drive innovation in the field of cancer immunotherapy. Get ready to connect with leading experts, explore cutting-edge discoveries, and shape the future of cancer treatment.

Stay tuned for more details on the 2025 conference that promises to inspire, educate, and propel us closer to our shared goal of conquering cancer through immunotherapy.

#ITOC2025 #Immunotherapy #SaveTheDate



## THE LEADING INTERNATIONAL CANCER IMMUNOTHERAPY CONFERENCE IN EUROPE

11<sup>th</sup> ImmunoTherapy of Cancer Conference  
April 3 – 5, 2025 • Munich, Germany



[www.itoc-conference.eu](http://www.itoc-conference.eu)

